Mr. Fabio Chianelli reports

REVIVE THERAPEUTICS LTD. ANNOUNCES RESULTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2015

Revive Therapeutics Ltd. has released its results for the three months ended Sept. 30, 2015. The unaudited condensed interim consolidated financial statements and related management's discussion and analysis for the three months ended Sept. 30, 2015, may be viewed on SEDAR.

Operational highlights

• Subsequent to its three months ended on Sept. 30, 2015, the company announced that the office of orphan products development of the U.S. Food and Drug Administration (FDA) has granted orphan designation status for the use of the drug Bucillamine for the treatment of cystinuria.
• Subsequent to its three months ended on Sept. 30, 2015, the company announced that Dr. Lee S. Simon, MD, will join Revive as senior clinical and regulatory affairs adviser for the company.
• Subsequent to its three months ended on Sept. 30, 2015, the company announced that the company's common shares have been listed for trading on the OTCQB market exchange in the United States under the symbol RVVTF. The company's common shares will continue to be traded on the TSX Venture Exchange under the symbol RVV.

Financial highlights

• Cash and cash equivalents at Sept. 30, 2015, totalled $1,790,469 (June 30, 2015 -- $2,492,072).
• The net loss for the three months ended Sept. 30, 2015, was $912,799 (Sept. 30, 2014 -- $398,588).
• The company's research costs for the three months ended Sept. 30, 2015, were $653,732 (Sept. 30, 2014 -- $154,799).

Fabio Chianelli, chief executive officer of Revive Therapeutics, commented, "I am pleased with the milestones that we have achieved to date as it paves the way for advancements in our product development programs in gout and cystinuria, and the potential to broaden our awareness with institutional and retail investors in the U.S."

We seek Safe Harbor.